ArticleCancer research2010
Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors.
Article in Cancer research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Exploring the potential bioactive compounds group and mechanism of Ci Bai Capsule in treating leukopenia: a combined approach of network pharmacology and transcriptome evidences.Chinese medicine · 2025Article
- Article
- Integrated transcriptomic and metabolomic profiles reveal the protective mechanism of modified Danggui Buxue decoction on radiation-induced leukopenia in mice.Frontiers in pharmacology · 2023Article
- G-CSF/GM-CSF-induced hematopoietic dysregulation in the progression of solid tumors.FEBS open bio · 2022Review
- Monitoring Spontaneous Quiescence and Asynchronous Proliferation-Quiescence Decisions in Prostate Cancer Cells.Frontiers in cell and developmental biology · 2021Article
- Sulfated polymannuroguluronate TGC161 ameliorates leukopenia by inhibiting CD4Carbohydrate polymers · 2020Article
- Article
- Human antigen R-regulated CCL20 contributes to osteolytic breast cancer bone metastasis.Scientific reports · 2017Article
- Bone Microenvironment Changes in Latexin Expression Promote Chemoresistance.Molecular cancer research : MCR · 2017Article
- A role for G-CSF and GM-CSF in nonmyeloid cancers.Cancer medicine · 2014Review
- Activation of the Wnt pathway through AR79, a GSK3β inhibitor, promotes prostate cancer growth in soft tissue and bone.Molecular cancer research : MCR · 2013Article
- Recruitment of coregulator G9a by Runx2 for selective enhancement or suppression of transcription.Journal of cellular biochemistry · 2012Article
- Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis.Cancer research · 2012Article
- Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer.Oncoimmunology · 2012Article
- Breast cancer at bone metastatic sites: recent discoveries and treatment targets.Journal of cell communication and signaling · 2011Article
- Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.Breast cancer research : BCR · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Hematopoietic growth factors are used to reverse chemotherapy-induced leukopenia. However, some factors such as granulocyte macrophage colony-stimulating factor (GM-CSF) induce osteoclast-mediated bone resorption that can promote cancer growth in the bone. Accordingly, we evaluated the ability of GM-CSF to promote bone metastases of breast cancer or prostate cancer in a mouse model of chemotherapy-induced leukopenia. In this model, GM-CSF reversed cyclophosphamide-induced leukopenia but also promoted breast cancer and prostate cancer growth in the bone but not in soft tissue sites. Bone growth was associated with the induction of osteoclastogenesis, yet in the absence of tumor GM-CSF, it did not affect osteoclastogenesis. Two osteoclast inhibitors, the bisphosphonate zoledronic acid and the RANKL inhibitor osteoprotegerin, each blocked GM-CSF-induced tumor growth in the bone but did not reverse the ability of GM-CSF to reverse chemotherapy-induced leukopenia. Our findings indicate that it is possible to dissociate the bone-resorptive effects of GM-CSF, to reduce metastatic risk, from the benefits of this growth factor in reversing leukopenia caused by treatment with chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.